This report was first published by Endpoints News. To see the original version, click here
Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday.
Separately, Sanofi said the FDA issued a complete response letter for the BTK inhibitor, tolebrutinib, for certain multiple sclerosis patients.
您已阅读12%（382字），剩余88%（2920字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。